Novel approaches for retinal drug delivery
- PMID: 12434490
- DOI: 10.1016/s0896-1549(02)00034-2
Novel approaches for retinal drug delivery
Abstract
Novel methods of ophthalmic drug delivery are being developed to facilitate treatment of a variety of eye diseases. Pharmaceuticals administered intravitreally are able to bypass the blood-ocular barrier to achieve constant therapeutic levels in the eye, while minimizing systemic side effects. Sustained-release intravitreal implants are being developed to enhance further the intravitreal route of administration. Liposomes, microscopic vesicles with a membrane-like lipid bilayer surrounding an aqueous compartment, are being developed to incorporate a wide variety of drug molecules, proteins, nucleotides, and even plasmids giving them great potential for use in ophthalmology. Biodegradable scleral plugs containing pharmaceuticals have the advantage of biodegradability and the ability to fit in a relatively small diameter of 1 mm. Conjugate drugs, which are covalently linked, decrease drug solubility, which increases their half-life and also limits the amount of active drug present at a given time. Viral vectors have been investigated in the delivery of genetic material to the posterior segment of the eye. Retrovirus, adenovirus, adenoma-associated virus, herpes virus, and lentivirus have been investigated for gene transfer to the retina. Finally, iontophoresis, a method of drug delivery typically involving the application of low electric currents to drive molecules across barriers, such as skin, is being explored for ophthalmic applications.
Similar articles
-
Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.Med Hypotheses. 2017 Jun;103:5-9. doi: 10.1016/j.mehy.2017.03.033. Epub 2017 Apr 1. Med Hypotheses. 2017. PMID: 28571808
-
Intravitreal drug delivery in retinal disease: are we out of our depth?Expert Opin Drug Deliv. 2014 Oct;11(10):1575-90. doi: 10.1517/17425247.2014.927864. Epub 2014 Jun 14. Expert Opin Drug Deliv. 2014. PMID: 24931577 Review.
-
Lipid nanoparticles as drug/gene delivery systems to the retina.J Ocul Pharmacol Ther. 2013 Mar;29(2):173-88. doi: 10.1089/jop.2012.0128. Epub 2013 Jan 3. J Ocul Pharmacol Ther. 2013. PMID: 23286300 Review.
-
The role of blood-ocular barrier transporters in retinal drug disposition: an overview.Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1111-24. doi: 10.1517/17425255.2010.486401. Expert Opin Drug Metab Toxicol. 2010. PMID: 20438316 Review.
-
A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.J Pharm Sci. 2010 May;99(5):2219-39. doi: 10.1002/jps.21987. J Pharm Sci. 2010. PMID: 19894268 Review.
Cited by
-
Novel Eye Drop Delivery Systems: Advance on Formulation Design Strategies Targeting Anterior and Posterior Segments of the Eye.Pharmaceutics. 2022 May 27;14(6):1150. doi: 10.3390/pharmaceutics14061150. Pharmaceutics. 2022. PMID: 35745723 Free PMC article. Review.
-
Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review.J Ophthalmol. 2021 May 17;2021:6678364. doi: 10.1155/2021/6678364. eCollection 2021. J Ophthalmol. 2021. PMID: 34055398 Free PMC article. Review.
-
Biodegradable Nanoparticle for Cornea Drug Delivery: Focus Review.Pharmaceutics. 2020 Dec 18;12(12):1232. doi: 10.3390/pharmaceutics12121232. Pharmaceutics. 2020. PMID: 33353013 Free PMC article. Review.
-
Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations.Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):159-179. doi: 10.1097/APO.0000000000000290. Asia Pac J Ophthalmol (Phila). 2020. PMID: 32511120 Free PMC article. Review.
-
Gene Therapy in Retinal Dystrophies.Int J Mol Sci. 2019 Nov 14;20(22):5722. doi: 10.3390/ijms20225722. Int J Mol Sci. 2019. PMID: 31739639 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical